Novo Nordisk plans phase 3 clinical studies for amycretin, a dual GLP-1 and amylin receptor agonist, targeting overweight and obesity. Early trials showed significant weight loss with both injectable and oral forms. Phase 3 enrollment is expected to commence in early 2026 following favorable regulatory feedback. The move expands Novo’s obesity pipeline amid competitive pressures, aiming to improve efficacy beyond current standards like Wegovy.